Great Point Partners’s Medicines Co MDCO Stock Holding History

Great Point Partners’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-750,000	Closed	-$25.5M	–	49
2016 Q4	$25.5M	Buy	+750,000	New	+$26.6M	5.23%	8

Other funds holding MDCO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Great Point Partners's MDCO Position: Q4 2015 in Review

Great Point Partners sold out of Medicines Co (MDCO) in Q4 2015, closing a stake of 150,000 shares — an estimated $5.69M sold.

Great Point Partners first reported a position in MDCO in Q3 2015 and held it in 1 quarter. The position peaked at $5.69M in Q3 2015. 190 funds tracked by Wall St. Rank hold MDCO as of Q4 2015.

Great Point Partners reported no remaining Medicines Co position as of Q4 2015 after selling out during the quarter.
Great Point Partners sold 150,000 Medicines Co shares in Q4 2015, an estimated $5.69M.
Great Point Partners first reported a position in Medicines Co in Q3 2015 and held it in 1 quarter.
Great Point Partners's Medicines Co position peaked at $5.69M in Q3 2015.
190 funds tracked by Wall St. Rank held Medicines Co as of Q4 2015.

Based on Great Point Partners's 13F filing for Q4 2015, filed 16 Feb 2016.